Skip to content

Real-World Observational Study on the Use of Biologics for Seasonal Allergic Rhinitis

Real-World Observational Study on the Use of Biologics for Seasonal Allergic Rhinitis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106163
Enrollment
Unknown
Registered
2025-07-18
Start date
2025-07-25
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal allergic rhinitis

Interventions

2 weeks (± 3 days) before the start of pollen season group:None
1 week (±3 days) before the start of pollen season group:None
After the start of the pollen season (within 3 days) group:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age: 6 to 65 years old; 2.Typical SAR for >=2 years, with obvious symptoms still after receiving anti-allergy treatment; 3.Pollen corresponding to the season (spring: cypress pollen, etc.) Autumn: Serum sIgE level >= grade 2 (Uni-CAP detection system) of Artemisia, Humulus, ragweed or chenopodiaceae pollen, etc; 4.For patients with asthma, pulmonary function FEV1>=80% of the predicted value, and FEV1/FVC>=70%; 5.The doctor prescribed biological agents for the treatment of SAR and voluntarily participated in this observational study.

Exclusion criteria

Exclusion criteria: 1. Non-allergic rhinitis (such as drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, acute/chronic sinusitis, dry rhinitis, atrophic rhinitis, severe deviated septum); 2. Clinical manifestations are simple perennial AR; 3. Pregnancy or lactation; Women who are unwilling to use contraception for the duration of the study; 4. Uncontrolled asthma or severe asthma and irreversible respiratory obstructive diseases, severe cardiovascular diseases, acute and chronic infectious diseases, autoimmune or immunodeficiency diseases, malignant tumors, mental disorders, oral diseases, etc.; 5. Use of biological agents within 3 months; 6. Use of systemic glucocorticoids within 4 weeks; 7. Concomitant medications that other doctors consider inappropriate.

Design outcomes

Primary

MeasureTime frame
Combined Symptom and Medication Score, CSMS;

Countries

China

Contacts

Public ContactPan Zhouxian

Peking Union Medical College Hospital

panzhouxian@pumch.cn+86 10 69151601

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026